Clinical Trial Update: A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluating CTX131 in adults with relapsed or refractory hematologic malignancies, assessing safety and efficacy across T-cell lympho…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• B-cell Lymphoma
• T-cell Lymphoma

Drugs mentioned

• CTX131

Snippet

Sponsor: CRISPR Therapeutics | Conditions: T Cell Lymphoma, B Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED